ORKA-001 Updated Nov 9
The key catalyst to watch is the EVERLAST-A 52-week data expected in December 2026, which will demonstrate whether ORKA-001's skin-clearing responses hold up a full year after just two doses. Strong durability would reinforce the ultra-durable dosing thesis and support the Phase 3 design. Weak durability would challenge the core value proposition. Phase 3 initiation in 1H 2027 and ORKA-002 Phase 2 data in Q1 2027 are secondary catalysts. The $1.1B cash runway removes financing overhang through a BLA filing.
- Highly consistent efficacy across two independent Phase 2 trials: 61-63% complete skin clearance (PASI 100) at Week 16, with responses deepening to 71% at Week 28 without additional dosing
- Ultra-long dosing interval potential (1-2 injections per year) could be a significant competitive advantage over current IL-23 inhibitors that require dosing every 8-12 weeks
- $1.1 billion cash position funds operations through BLA filing, eliminating near-term dilution risk
- Still a clinical-stage company with no approved products; regulatory and commercial risks remain significant
- Cross-trial comparisons to approved IL-23 inhibitors (Skyrizi, Tremfya) are not head-to-head; Phase 3 data may show different relative efficacy versus these entrenched multi-billion-dollar brands
- Stock has already rallied substantially (52-week range $25-$115, up roughly 4x from lows), potentially pricing in success before Phase 3 data